AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05392855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom driven performance of airway clearance
Description: Perform symptom driven/intermittent airway clearance therapy with frequency based off of patient's daily symptoms including mobilization therapy (high-frequency chest compression or vest device, intrapulmonary percussive ventilator, positive expiratory pressure device) and inhaled/nebulized therapies of albuterol, hypertonic saline and dornase alfa for the 12 week study period.
Study NCT05392855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous daily performance of airway clearance
Description: Continue run-in protocol of twice daily airway clearance using twice daily mobilization therapy (high-frequency chest compression or vest device, intrapulmonary percussive ventilator, positive expiratory pressure device) and inhaled/nebulized therapies of albuterol, hypertonic saline and dornase alfa for the 12 week study period.
Study NCT05308472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DISC-1459
Description: Oral dose level 1, once a day for 120 days
Study NCT05308472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DISC-1459
Description: Oral dose level 2, once a day for 120 days
Study NCT05308472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose, once a day for 120 days
Study NCT05308472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DISC-1459
Description: Oral dose level 1, once a day for up to 8 months
Study NCT05978960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition and resistance training exercise intervention
Description: 3 month 2-3 times/week, 60 min exercise regimen utilizes compound movements to focus on body composition, strength, and mobility. Classes are run by certified strength and conditioning specialists and adjusted for linear progression and safety, progressing from compound to isolated movements to maximize safety.~The nutrition intervention focuses on dietary quality by following a healthy low-carbohydrate diet, focusing on nutrient dense foods high and avoiding processed foods and simple carbohydrates to keep totals under 100g/day. Participants will be advised to eat vegetables, avoid snacking, cook all meals with family and friends, avoid eating on the run, and focus on whole foods that require preparation. Calculations and quantification of calories will be avoided, while protein consumption goals are 1.3-1.8 g/kg per. Dietary strategy will be continuously discussed during exercise sessions and the PI will have twice monthly meetings with participants.
Study NCT04958044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Gluconate
Description: Calcium electroporation
Study NCT06014372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: Upon confirming eligibility based on inclusion criteria and obtaining signed informed consent, the patient will be administered Envafolimab at a dose of 300mg every 3 weeks (Q3W) for a total of 4 cycles, starting on Day 1.
Study NCT06014372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envafolimab
Description: Upon confirming eligibility based on inclusion criteria and obtaining signed informed consent, the patient will be administered Envafolimab at a dose of 300mg every 3 weeks (Q3W) for a total of 4 cycles, starting on Day 1.
Study NCT06014372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPEOX
Description: The neoadjuvant treatment regimen will consist of Oxaliplatin at a dose of 130mg/m2, administered intravenously over a period of more than 2 hours on Day 1, every 3 weeks; and Capecitabine at a dose of 1000mg/m2, orally, twice daily from Day 1 to Day 14, every 3 weeks, for a total of 4 cycles.
Study NCT05866575 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: escitalopram
Description: Patients will receive an antidepressant strategy : escitalopram. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
Study NCT05866575 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: vortioxetine
Description: Patients will receive an antidepressant strategy : vortioxetine. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the treatment strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
Study NCT05008848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive NCI's Clearing the Air booklet
Study NCT05008848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05308264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R906289 Monosodium (R289 Na)
Description: Drug: R906289 Monosodium (R289 Na) R906289 Monosodium (250mg PO qd,500 mg PO qd, 750 mg PO qd, 1000 mg PO qd)
Study NCT04945551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: 12 weeks intervention period consisting of aerobic exercise training 3 sessions/week, 45 min/session. All training sessions are supervised. Aerobic training is conducted as ergometer bicycle training at an intensity of 70% of maximal oxygen uptake (x2/wk.) and rowing ergometer exercise at 70% of maximal heart rate (x1/wk.). In week 3, 6 and 9 VO2 max is measured to ensure sufficient adjustment of the workload during the training sessions.
Study NCT05745779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c, Vitamin D, Vitamin B12
Description: Serum HbA1c, Vitamin D, Vitamin B12 values of the patients who applied for gingival treatment in the last 3 months from the date of application were found from the hospital archive and serum was not taken from the patients again for the study.
Study NCT06371053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Intervention
Description: The intervention includes Cognitive Training: Activities targeting memory, attention, language, and executive functions to maintain cognitive abilities. This could involve cognitive games, memory exercises, and daily tasks.~Life Skills Training: Assistance in maintaining or relearning daily life skills such as personal hygiene, dressing, eating, and household chores. This could be through structured training programs and daily guidance.~Physical Exercise: Providing appropriate physical activities and exercises to maintain physical health and function, including walking, balance training, and light strength training.~Social Support: Organizing social activities and support groups to facilitate interaction and reduce social isolation and loneliness.~Emotional Support: Offering mental health support and psychosocial services to help individuals cope with emotional challenges such as anxiety and depression.
Study NCT04776499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propylthiouracil, Riociguat, Perphenazine
Description: Administration of propylthiouracil, riociguat, and perphenazine in combination~Investigational medicinal product (IMP):~Propylthiouracil: 100 mg, Riociguat: 1 mg, Perphenazine: 16 mg
Study NCT06043076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Active iTBS will be applied using a butterfly figure-of-eight C-B60 coil connected to MagPro R30 stimulator with add-on Theta Burst option (MagVenture A/S, Farum, Denmark).
Study NCT05801380 — intervention group
Intervention type: DRUG
Intervention: AChE inhibitor monotherapy
Description: This is a drug treatment using Donepezil only
Study NCT05801380 — intervention group
Intervention type: DRUG
Intervention: AChE inhibitor and NMDA receptor antagonist combination therapy
Description: This is a drug treatment combining Donepezil and Memantine
Study NCT05433051 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: buccal miniscrew and TPA
Description: intrusion of molars
Study NCT05433051 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: vertical holding appliance
Description: intrusion of molars
Study NCT06043076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Sham iTBS will be applied using acoustic stimulation of a second coil behind the participant's head
Study NCT05427539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEST LENS
Description: AO1DfA manufactured with PG hydration
Study NCT05427539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTROL LENS
Description: AO1DfA manufactured with IPA hydration
Study NCT05940207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-Bandages
Description: A hydrogen-peroxide generating e-bandage for wound infection and treatment and prevention. Each e-bandage is composed of three electrodes - a working, a counter, and a reference electrode. Cotton fabric physically separates electrodes. Constant (regulated) generation of low-concentrations of hydrogen peroxide happens on the working electrode, which is in contact with the skin covered with a hydrogel layer.
Study NCT05511051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fruquintinib
Description: Fruquintinib
Study NCT05511051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib
Study NCT05511051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC
Description: HAIC
Study NCT05220280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Oral imatinib 400 mg tablet once a day for 14 days.
Study NCT05220280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab is administered as a single IV infusion with the proposed dosing schedule of 5 mg/kg body weight.
Study NCT05007470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSL #3 112.5 Capsule
Description: VSL#3 is a commercial probiotic mixture consisting of eight bacterial strains: Four strains of Lactobacillus (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus delbrueckii subspecies bulgaricus), three strains of Bifidobacterium (Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), and one strain of Streptococcus (Streptococcus salivarius subspecies thermophilus).
Study NCT05007470 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg sugar
Study NCT06102135 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Peptamen 1.3 PHGG
Description: The amount of tube feed will be assess by the health Care Professional.
Study NCT06490068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTC004+Toripalimab
Description: LTC004 on D1 of Week 1 and D1 of week 3. IV,90μg/kg. Beginning at week 5, all subjects will receive LTC004 in combination with Toripalimab.~LTC004:D3,iv,45μg/kg,Q3W. Toripalimab:D1,iv,240mg,Q3W.
Study NCT05130216 — intervention group
Intervention type: OTHER
Intervention: Genicular Nerve Radiofrequency Ablation
Description: Radiofrequency Ablation (RFA)
Study NCT05014295 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Accessing personal medical records online via online portals
Description: The participants will receive details on accessing personal medical records online via online portals, for each of the major hospital systems
Study NCT04648228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT+MBRP
Description: Intervention is behavioral treatment group that combines Acceptance and Commitment Therapy (ACT) with Mindfulness-Based Relapse Prevention. The group focuses on living with long-term pain, ways to complete daily living activities when you experience pain, coping with opioid and other drug cravings, and training in mindfulness practices.
Study NCT04648228 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education control
Description: Education control is behavioral treatment group that combines pain patient education with opioid and other drug education. The group focuses on experiences of long-term pain, instructions on how to function with this pain, and facts about opioids and other drugs.
Study NCT05852262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: 1000 mg PO QID for 7 days
Study NCT05852262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: 500 mg PO QID plus oral placebo for 7 days
Study NCT05566444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat stimulus
Description: Contact heat pain stimulus with a termode set at 46 degrees and contact warm stimulus with a termode set at 40 degrees
Study NCT06415955 — intervention group
Intervention type: OTHER
Intervention: None, pure observationnal study
Description: None, pure observationnal study
Study NCT05634746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APT-1011
Description: APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.~Other Names:~fluticasone propionate
Study NCT05634746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo orally disintegrating tablet.~Other Names:~PBO
Study NCT05634746 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus
Study NCT05634746 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Esophagogastroduodenoscopy
Description: Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus
Study NCT06045416 — intervention group
Intervention type: PROCEDURE
Intervention: venous blood puncture
Description: Venous blood puncture performed at first hospital contact, and at 28 days, 3 month, and 6 months after hospital admission.~Lumbar puncture and joint puncture for the study will be performed if it is indicated due to diagnostic or therapeutic reasons.
Study NCT04906720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: colchicine 0.6mg oral twice daily for 7 days
Study NCT04642898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard UP Treatment
Description: Participants will receive treatment modules sequenced in accordance with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al 2011; 2018).
Study NCT04642898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Capitalization UP Treatment
Description: Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that capitalize on patient strengths.
Study NCT04642898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compensation UP Treatment
Description: Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that compensate for patient weaknesses.
Study NCT06350669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation phone application
Description: The standard vestibular rehabilitation process, with the support of a phone app throughout the process
Study NCT05232864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: 300 mg solution for subcutaneous (s.c.) injection in a 2mL Pre-Filled Syringe (PFS)
Study NCT04634916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoAVF Creation
Description: Subjects will have an endoAVF created using the WavelinQ EndoAVF System
Study NCT05862129 — intervention group
Intervention type: PROCEDURE
Intervention: surgical operation
Description: Radical operation for the perianal abscess
Study NCT05770934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restricted low-load resistance exercise
Description: Blood flow restricted low-load resistance exercise
Study NCT06511089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: carotid artery stenting during EVT
Description: Patients with an ipsilateral high grade carotid artery stenosis or occlusion of presumed atherosclerotic origin and an proximal intracranial large vessel occlusion in the anterior circulation will be randomized using a web-based randomization tool to immediate carotid artery stenting or deferred treatment strategy of carotid artery stenosis.~In the intervention group, the cervical carotid artery lesion will be treated with a stent during the EVT (just before or directly after intracranial thrombus removal), the control group will be treated according to the national guidelines with carotid endarterectomy of carotid artery stenting (for patients with non-disabling stroke) or medical management alone (for patients with severe disabling stroke).
Study NCT06511089 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no carotid artery stenting during EVT
Description: A deferred treatment approach: carotid revascularization within two weeks after stroke onset or best medical management only, depending on the functional recovery of the patient.
Study NCT06635759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper trapezius low-load endurance exercise
Description: Participants in the EE group will perform the overhead shrug exercise for the affected side using a green Thera-Band Elastic Band. To perform this exercise, the subject will stand and place one arm of the affected side in an overhead position against the wall. The middle portion of the theraband will be placed on the floor, and the subject will stand on the middle portion of the theraband to fixate it in place with both feet shoulder-width apart. Then, the subject grasp both tails of the theraband and perform the shoulder shrug movement for the affected side with a 3-second elevation, hold at the end range for 5 seconds, and then return back to the starting position with a 3-second depression. The subject will perform this exercise for 20 repetitions per set, 3 sets a day with 1-minute rest between sets, 3 alternate days a week, for 5 weeks. They will be instructed to record all training sessions in a diary.
Study NCT06635759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper trapezius stretching exercise
Description: Participants in the SE group will perform static upper trapezius stretching exercise for the affected side. To perform the stretch, participants will be asked to sit upright on a chair and look straight ahead. To reduce scapular elevation and upward rotation, the ipsilateral hand should be placed below the buttock. The subject will then be asked to perform deep neck flexion, neck rotation towards the affected side, and contralateral side flexion using the opposite hand in a diagonal direction until the position of 'mild discomfort' is attained. They should maintain the deep neck flexion when performing the stretch. The stretch will be held for 30 seconds each set, 3 sets a day, daily for 5 weeks.
Study NCT04934033 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neurological assessments
Description: The participants will have a MRI, and language and cognitive assessments.
Study NCT04660799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab IV
Description: Rituximab will be administered intravenously through Cycle 1-8 at a standard dose of 375 mg/m\^2 (milligram per square meter).
Study NCT04660799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab SC
Description: Rituximab will be administered subcutaneously through Cycle 2-8 at a dose of 1400 milligram (mg).
Study NCT05360706 — intervention group
Intervention type: GENETIC
Intervention: AAV5-hFIX
Description: AAV5 containing a codon-optimized human factor IX gene
Study NCT05230225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician Notification Letter
Description: Receiving the electronic Physician Notification Letter to highlight echocardiography results that are consistent with or may be consistent with severe AS and to be reminded of ACC/AHA Clinical Practice Guideline recommendations regarding the management of severe AS.
Study NCT05171608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-based protocol based fluid therapy
Description: Protocol of the interventional group according to the ultrasonographic findings:~Ultrasound scan 2 hours before surgery:~IVCCI>40 percent and absence of symmetric anterior 'B-profile' on the lung ultrasound indicate intravenous (IV) fluid therapy: 8 ml/kg of isotonic, balanced crystalloid infusion.~IVCCI≤40 percent AND/OR symmetric anterior 'B-profile' contraindicates further IV fluid therapy.~A 2nd ultrasound scan at 30 minutes before surgery:~IVCCI>40 percent and absence of symmetric anterior 'B-profile' on the lung ultrasound indicate further IV fluid therapy: 5 ml/kg of isotonic, balanced crystalloid infusion.~IVCCI≤40 percent AND/OR symmetric anterior 'B-profile' contraindicates further IV fluid therapy.
Study NCT04660799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab IV
Description: Rituximab will be administered intravenously in Cycle 1 at a standard dose of 375 mg/m\^2.
Study NCT04660799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered IV at a dose of 750 mg/m\^2
Study NCT04660799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered IV at a dose of 750 mg/m\^2
Study NCT04660799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin will be administered IV at a dose of 50 mg/m\^2
Study NCT04660799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered IV at a dose of 50 mg/m\^2